Case Report Neuroendocrine Cell Carcinoma of Unknown Primary Arising in Long Standing History of Multiple Sclerosis by Stergios Boussios et al.
Case Report
Neuroendocrine Cell Carcinoma of Unknown Primary Arising in
Long Standing History of Multiple Sclerosis
Stergios Boussios,1 Vasiliki Kostadima,2 Anna Batistatou,3 Ioannis Tourkantonis,1
George Fotopoulos,1 Maria I. Argyropoulou,4 and Nicholas Pavlidis1
1Department of Medical Oncology, Medical School, University of Ioannina, 45110 Ioannina, Greece
2Department of Neurology, Medical School, University of Ioannina, 45110 Ioannina, Greece
3Department of Pathology, Medical School, University of Ioannina, 45110 Ioannina, Greece
4Department of Radiology, Medical School, University of Ioannina, 45110 Ioannina, Greece
Correspondence should be addressed to Nicholas Pavlidis; npavlid@uoi.gr
Received 11 December 2014; Accepted 16 March 2015
Academic Editor: Francesca Micci
Copyright © 2015 Stergios Boussios et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Multiple sclerosis (MS) is a chronic autoimmune disease that targets myelinated axons in the central nervous system (CNS). Cancer
of unknown primary site (CUP) is a well-recognised clinical disorder, accounting for 3–5% of all malignant epithelial tumors.
CUP is clinically characterised as an aggressive disease with early dissemination. Studies of cancer risk in MS patients have shown
inconsistent findings. An increased risk of malignancy in patients with MS has been suggested, but recently serious questions have
been raised regarding this association. Use of disease-modifying therapies might contribute to an increased cancer risk in selected
MS patients. The concurrence of MS and CUP is exceptionally rare. Here we describe the case of a neuroendocrine carcinoma
of unknown primary diagnosed in a male patient with a nine-year history of MS. The discussion includes data from all available
population-based register studies with estimates of certain malignancies in patients with MS.
1. Introduction
MS affects almost 1.3 million people worldwide [1]. Although
the underlying cause of this entity is unknown and the
etiology is not well understood, it is thought to be an
autoimmune disease mediated by the degradation of myelin
and destruction of axons in the CNS.
CUP is defined as histologically confirmed metastases
in the absence of identifiable primary tumor despite a stan-
dardized diagnostic approach [2]. CUP accounts for 3–5%
of all cancers, with a reported annual incidence per 100,000
population of 18 cases in Australia, 7–12 cases in the US, and
six cases in Netherlands, ranking as the fourth commonest
cause of cancer death in both sexes [3].
Here, we describe for the first time in the literature a case
of neuroendocrine CUP which presented in a patient with
long standing history ofMS.Meanwhile, we review the litera-
ture in order to determine the underlying risk of cancer devel-
opment in MS patients compared to the general population.
Since 2003, patients with CUP are distinguished into
favourable and unfavourable groups. Favourable CUP group
represents the 20% of the cases and experiences bet-
ter responses to locoregional and/or systemic treatment
and longer survival. Neuroendocrine CUP belongs to the
favourable group [4].
2. Case Report
Our patient was first admitted to the neurology department
of our hospital in October 2005 at the age of 52 years
old because of disequilibrium. Preceding symptoms were
also reported, including bilateral numbness of the lower
legs and progressive weakness at the left leg attributed to
hip replacement. As the patient was alcoholic, the initial
explanation of the clinical picture was the polyneuropathy.
At this time, a lumbar spine computed tomography (CT)
scan was performed which disclosed a stenosis. Magnetic
resonance imaging (MRI) of the brain revealed multiple
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Figure 1: Left parasagittal FLAIR image of the brain of the patient
at the time of his relapse (March 2012). Multiple bright white matter
lesions with the long axis perpendicular to the surface of the lateral
ventricle compatible with multiple sclerosis.
lesions bright on T2-weighted images and enhancing after
IV contrast administration. The cerebrospinal fluid (CSF)
analysis detected an increased immunoglobulin G (IgG) or
Link index (0.82) and positive CSF-specific oligoclonal bands
by isoelectric focusing, without evidence of barrier injury.
CSF tests were negative for virus isolation and for Gram
stain and culture. A survey for vasculitis, including anti-
nuclear antibody (ANA) and anti-phospholipid antibody, was
negative too. During the following period, he experienced
occasional relapses, mainly spinal and brainstem attacks with
progression of his left legmotor weakness and incoordination
in the upper limbs. He was treated for his relapsing-remitting
disease with interferon beta-1a (IFN𝛽-1a), beginning in 2007;
treatment was switched in 2008 to IFN 𝛽-1b, because of a
breakthrough spinal attack with increasing disability and less
satisfactory response to steroids, with incomplete recovery.
His disease then became more steadily progressive. In 2008,
the patient underwent thoracic discectomy due to cervical
spinal stenosis associated with hypertrophic degenerative
changes. In March 2012, he presented with asymmetrical
spastic paraparesis, generalized increased reflexes, spastic and
ataxic gait, and moderate arm, leg, and truncal dysmetria.
Neurologic examination revealed atrophy of intrinsic hand
muscles. Gradual decline in cognition was also reported.
Because of these new symptoms, the patient underwent brain
MRI, which revealed multiple lesions involving supratento-
rial and infratentorial structures with cerebral and cerebellar
atrophy on the T2-weighted images. Lesions of the periven-
tricular white matter were perpendicular to the wall of the
lateral ventricles (Figure 1). Normal results for blood testing
and cancer workup were detected. After gadolinium contrast
injection, ring enhancement over these lesions was noted on
T1-weighted images. Thus, IFN-𝛽-1b was discontinued and
glatiramer acetate was begun which has been maintained
without further deterioration.
InMay 2014, the patient presented with pain and swelling
of the left side of his neck in association with a sore throat
and chest tightness. The pain radiated to the left axilla and
shoulder. There was no history of fever or night sweats. On
examination, there was diffuse tender swelling on the left side
of neck with a few scattered small tender lymph nodes in the
posterior triangle of the left side of the neck.The remainder of
clinical examination and the initial laboratory investigations
were normal. Ultrasound of the neck demonstrated enlarged
lymph nodes in the left supraclavicular fossa which were
suspicious of malignancy. The patient underwent an exci-
sional biopsy which revealed replacement of normal node
architecture by metastatic neuroendocrine tumor (Figure 3).
Positive immunohistochemical markers were neuron specific
enolase, cytokeratin- (CK-) AE1/AE3, CK8/18, and chromo-
granin (Figure 4). The neuroendocrine features in the case of
our patient were identified by immunohistochemical staining
for chromogranin. However, the positivity was almost 20%
which is moderate to strong staining intensity. These tumors
have been termed “poorly differentiated neuroendocrine
tumors” of unknown primary site. In order to find out the pri-
mary site the patient underwent panendoscopy of his upper
aerodigestive tract which was normal. Further investigations
failed to establish a possible primary site. This included
proctosigmoidoscopy, tumor marker study, and CT scan of
paranasal sinuses. A subsequent positron emission tomog-
raphy also failed to identify a primary site malignancy and
detected metastatic infiltration to the bilateral superior deep
cervical nodes and axillary and right inguinal lymph nodes.
No other lesions were demonstrated, with the liver and lungs
in particular appearing normal. A diagnosis of metastatic
neuroendocrine tumor of unknown primary site was eventu-
allymade and the patientwas referred to the oncology depart-
ment. He received palliative radiation to cervical and supra-
clavicular lesions to relieve local symptoms and he achieved
a partial response. No chemotherapy was attempted at that
time in order to avoid additional toxicity. After 10 months of
follow up he complained of a palpable mass in his left neck.Α
CT scan of the neck demonstrated the presence a mass lesion
with central necrosis and peripheral enhancement compati-
ble with local relapse (Figure 2). As the favorable risk subsets
should be treated similarly to patients with equivalent known
primary tumors with metastatic dissemination, a platinum-
based combination schedule was attempted. Although a
partial clinical response was detected after two cycles, the
patient stopped chemotherapy due to grade IV myelotoxicity
and to exacerbation of his neurological syndrome.
3. Discussion
Concurrence of CUP and MS has not been reported in the
literature. Here, we describe an intriguing case of overlap
between these two entities.
Multiple studies have examined the relationship between
MS and cancer risk. The majority of these analyses have
concluded that there is no difference in the risk of developing
malignancies between patients with MS and the general
population. However, some studies have suggested either
increased risk in breast, brain, and bladder tumors, in patients
with MS, or reduced risk in cancers of the digestive and
respiratory tract.
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Figure 2: Axial postcontrast CT image of the neck showing left lym-
phadenopathy with necrotic center and peripheral enhancement.
Figure 3: Infiltration of the lymph node by a metastatic neo-
plasm consisting of ovoid cells, with “salt and pepper” nuclei
(haematoxylin-eosin stain ×400).
A small but significantly increased risk of breast cancer
in patients with MS was reported in a few studies. Although
the Danish MS Registry (DMSR) study failed to show an
increased overall cancer risk in women with MS (SIR, 1.01),
there was an increased risk of breast cancer (SIR, 1.21)
[5]. The study also revealed that patients with MS tended
to have larger tumors at diagnosis compared with patients
without MS. The etiology of the increased breast cancer risk
in MS patients is currently obscure and deserves further
investigation.
Reports of MS mimicking brain tumors clinically and
radiologically could potentially explain the reverse associa-
tion of brain cancer before MS [6, 7], as could a brain tumor
associated with T2 hyperintensity on MRI mimicking MS. In
the British Columbia MS cohort, the nonsignificant elevated
risk for brain cancer was most evident in a short time after
disease onset. The diagnostic workup of MS may provide
an explanation (i.e., surveillance bias) and is in accordance
with other reports that have observed an increased risk [8–
11]. Other studies have found no significant increase in brain
cancer risk [5, 12–14].
Figure 4: On immunohistochemical examination the cells stained
positive for chromogranin (DAB ×400).
In the DMSR study, the risk of bladder cancer overall was
not statistically significantly increased [SIR = 1.19 (0.93–1.51),
𝑛 = 66] [5]. Moreover, female MS patients demonstrated
an increasing risk of bladder cancer in excess of 10 years
after MS onset [SIR = 1.58 (1.04–2.40), 𝑛 = 22]. On the
other hand, the risk of bladder cancer in men was increased
1 to 9 years after MS diagnosis [SIR = 2.09 (1.23–3.52),
𝑛 = 14] [5]. Approximately, the same results were obtained
in the British Columbia MS cohort concerning the risk of
developing bladder cancer (SIR: 1.21; 95% CI: 0.73–1.88) [8].
The reduced risk of digestive tract cancers in British
Columbia cohort is in accordance with findings from the
Oxford record linkage study (ORLS) [10], studies from
Scandinavia [12], France [14], and a US veterans study
[15], although not always statistically significant. Several
epidemiologic studies have suggested that long-term users
of nonsteroidal anti-inflammatory drugs (NSAIDs) have
a lower risk of colorectal cancers compared to nonusers
[16–19]. Whether the reduced cancer risk of digestive organs
in MS patients in a true phenomenon or due to lifestyle
factors or medications was used remains to be elucidated.
A total of five studies, reporting measures of the risk of
lung cancer for an MS cohort relative to population controls,
were studied [5, 9, 10, 12, 14]. The heterogeneity between
the studies was not significant (𝑃 = 0.87). Interestingly
enough, it has reported a significantly decreased risk of lung
cancer in the MS cohort relative to controls [OR 0.67 (95%
CI 0.59–0.76) 𝑃 < 0.00001] [20]. A possible explanation of
the decreased lung cancer prevalence would be the increased
immune surveillance in MS. The considerable reduction in
lung cancer inMS patients despite a predicted increase in risk
provides assurance with intensive in vitro and in vivo study
of mechanisms underlying this point.
Since 1993 several disease-modifying agents were intro-
duced and proven to alter the natural history ofMS, including
IFN-𝛽1b, IFN-𝛽1a, and glatiramer acetate. IFN-𝛽 blocks the
potent proinflammatory agent IFN-𝛾 and other inflamma-
tory cytokines that can cause immune-mediated damage to
myelin cells [21–23]. Glatiramer acetate is a synthetic polymer
of amino acids that was designed to mimic myelin basic
protein and act as a decoy to lessen autoimmune-mediated
damage to actualmyelin cells [24]. Newer research has shown
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that the drug is involved in a TH1-TH2 shift and subsequent
increased secretion of anti-inflammatory cytokines [25].
4. Conclusions
The majority of the evidence currently suggests that patients
with MS are not at an overall increased risk for the devel-
opment of cancer, apart from a possibility of breast, bladder,
and brain neoplasms. In addition, there is some evidence for a
reduced cancer risk for digestive tract organs and respiratory
organs.
We assume that our unusual report, in addition to the
literature on the concurrence of cancer and MS, might
be useful to stimulate further analyses about the serious
questions that have been raised regarding this association.
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